CureVac to Exit Public Markets Following BioNTech Acquisition

The publicly traded chapter for CureVac is drawing to a close. The company’s shares will soon be removed from the Nasdaq exchange, marking a definitive end for investors following the completion of a corporate reorganization triggered by a takeover bid from BioNTech. All operational business will now fall under BioNTech's full control.

CureVac has formally notified the Nasdaq Global Market of its acquisition's completion and requested a trading halt for its stock. The company has simultaneously commenced the official procedure to delist its shares from the exchange.

Specifically, CureVac has instructed Nasdaq to file a "Notification of Removal from Listing" (Form 25) with the U.S. Securities and Exchange Commission (SEC). This filing will seek to officially delist the equity from Nasdaq and terminate its registration under the Securities Exchange Act of 1934. The delisting is expected to become effective on January 16, 2026. From that date forward, CureVac will no longer be traded on public equity markets.

BioNTech Assumes Full Ownership

This move follows BioNTech's successful completion of its exchange offer for all outstanding ordinary shares of CureVac. As a result, BioNTech now exercises complete control over CureVac's business activities.

Should investors sell immediately? Or is it worth buying CureVac?

The transaction involved the creation of a successor entity, CureVac Merger B.V. The reorganization means CureVac no longer has any public shareholders; all equity is attributable to BioNTech.

Final Legal Steps and Market Impact

The acquisition and subsequent delisting represent a significant shift for the firm and the mRNA sector, as CureVac's future development will now occur entirely under the umbrella of its former competitor, BioNTech. Key developments include:

• Sole Owner: BioNTech is now the exclusive owner of the CureVac business.
• Trading Halt: CureVac has requested the suspension of its share trading on Nasdaq.
• No Public Float: The reorganization has eliminated all public shareholders.
• Delisting Date Set: The final removal from Nasdaq is scheduled for January 16, 2026.

Following the delisting, CureVac Merger B.V. intends to file a Form 15 with the SEC. This action will terminate the registration of its shares and suspend all ongoing reporting obligations to the U.S. securities regulator. This final step will formally conclude CureVac's withdrawal from the public capital markets.